Dual endothelin-converting enzyme/neutral endopeptidase inhibition: A novel treatment for renovascular hypertension beyond blood pressure lowering?

Hypertension

Volumn 57, Issue 4, 2011, Pages 667-669

  Dhaun, Neeraj ^a,b   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; SLV 388; UNCLASSIFIED DRUG;

BLOOD PRESSURE MONITORING; DIABETIC NEPHROPATHY; DRUG ACTIVITY; EDITORIAL; ENZYME INHIBITION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ASPARTIC ACID ENDOPEPTIDASES; BLOOD PRESSURE; HYPERTENSION, RENOVASCULAR; METALLOENDOPEPTIDASES; NEPRILYSIN; RATS;

EID: 79953211460     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.166876     Document Type: Editorial

References (15)

1. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Nat Acad Sci USA. 1989;86:2863-2867. (Pubitemid 19112640)
2. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond). 1993;84:485-500. (Pubitemid 23131961)
3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348:730-732. (Pubitemid 120015147)
4. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature. 1990;348:732-735. (Pubitemid 120015148)
5. Davenport AP, O'Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 1993;22:22-25.
6. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756. (Pubitemid 28135337)
7. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Soc Exp Biol Med. 2006;231:653-695. (Pubitemid 43845510)
8. Webb DJ. DORADO: opportunity postponed-lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension. 2010;56:806-807.
9. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol. 2006: 295-329.
10. Samson WK, Skala KD, Alexander B, Huang FL. Possible neuroendocrine actions of endothelin-3. Endocrinology. 1991;128:1465-1473.
11. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323-2330. (Pubitemid 28280386)
12. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension. 2011;57:755-763.
13. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci. 1998;13:170-176.
14. Thone-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormahlen D, Hocher B. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44:76-79.
15. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005;45:1145-1152. (Pubitemid 40770319)